Patient reported outcomes in adults with severe eosinophilic asthma on benralizumab. - POWER

Exclusion Criteria

• The following individuals may be eligible to participate:
• •Are enrolled in the benralizumab PSP;
• •Are 18 years of age or older;
• •Can understand the requirements of the study and provide informed consent to participate in this study;
• •Agree to abide by the study protocol and the exclusion criteria and can complete all aspects of the study, including all visits.
• •Are benralizumab naïve and have not previously received benralizumab prior to the start of this study
• AND
• •Suffer from uncontrolled severe eosinophilic asthma meeting at least one of the following:
• 1.Has blood eosinophil count ≥ 300 cells/μL AND experienced two or more clinically-significant exacerbations in the past 12 months;
• OR
• 2.Has blood eosinophil count ≥ 150 cells/μL AND are treated chronically with oral corticosteroids (OCS);
• OR
• 3.Sputum eosinophil levels of 3% and higher
• OR
• 4.Have been previously treated with a biologic for severe asthma and previously met the above eosinophil counts (detailed in #1,2, or 3 above) prior to initiation of the previous biologic.
• AND
• •ACQ-6 score ≥ 1.5
• Any of the following conditions are cause for exclusion from the study:
• •Patients currently enrolled in an interventional clinical study in parallel will be excluded from the study, except for patients who are in parallel documented in a national asthma registry;
• •Patients who have previously received benralizumab prior to the start of the study
• •Patients currently participating (i.e. have not completed) in any other clinical trial including those with biologic treatment;
• •Patients with other documented lung disease other than asthma and not within reimbursed label.